ABSTRACT
Study References
A review of use of PSA in screening of prostate cancer 64
A review on the use of biomarker in breast cancer focusing on the use of blood-based markers and breast-based markers with emphasis on the identi€cation of biomarkers for early detection of breast cancer in asymptomatic patients
A review of screening methods for colorectal cancer. Fecal occult blood testing (FOBT) remains the most useful screening method. Since colonic epithelial cells are replaced every 3-4 days, stool samples are of interest for the identi€cation of DNA markers, which might be of value. Proteins such as calprotectin are stable in stool samples but are nonspeci€c indicators of in†ammation
Proteomic analysis of exhaled break condensate as a source of biomarkers for lung cancer screening
A review of the current status of ovarian cancer screening based on the premise that a successful screening test must demonstrate a positive effect on ovarian cancer mortality while achieving the high speci€city required to minimize down-side from false-positive results
A review of the use of biomarkers for the diagnosis of oral squamous cell carcinoma using negative/positive cell selection strategies for the enrichment of oral tumor cells and use of microarray technology to identify tumor biomarkers within the concept of lab-on-a-chip technology
DNA methylation as biomarker for screening for colorectal cancer using stool or serum samples
Fecal calprotectin as screening biomarker for colorectal cancer was evaluated in prospective study. The results suggest that fecal calprotectin was a poor biomarker for colorectal cancer; it is suggested that a tumor-based biomarker will be more useful than a blood-based biomarker
Development of a micro†uidic chromatography system for biomarker screening. The micro†uidic analysis of protein digest (shotgun/tryptic hydrolysis/prefractionation with strong cation exchange) permitted the identi€cation of cancer-speci€c proteins
Use of multiplexed immunobead-based biomarker pro€ling for screening for head and neck cancer. The use of a multiplexed platform recognizing 25 biomarkers was found to be the most discriminating. Biomarkers included cytokines, growth factors, receptors, and tumor markers
Papillomavirus as a screening biomarker for cervical cancer screening 218
Autoantibody to alpha-2HS glycoprotein for breast cancer screening 219
Biomarkers (CRP, cell adhesion molecules, methylarginine) combined with clinical markers(†ow-mediated vasodilation, carotid intima media thickness, arterial stiffness) to provide surrogate vascular markers to identify youth at risk for premature cardiovascular disease
Altered microRNA expression (RT-PCR) in sputum for diagnosis of non-small-cell lung cancer
B-type natriuretic peptide (BNP) is in routine use as a biomarker for cardiac failure.b This study demonstrates its usefulness for screening in a pediatric population
Elevation of serum metallothionein as a biomarker for cancer 223
Study References
Fucosylation as biomarker for heptocellular carcinoma (HCC). Fucosylated kininogen and fucosylated α-1-antitrypsin were signi€cantly higher (P <0.0001) in HCC patients. The combination of these two biomarkers with Golgi protein 73 provided a sensitivity of 95% and a speci€city of 70%.
